Search for more clinical trials
Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
Conditions
Recurrent or Refractory Primary CNS Lymphoma
Conditions: official terms
Lymphoma
Conditions: Keywords
temsirolimus, primary CNS lymphoma, PCNSL, salvage treatment
Study Type
Interventional
Study Phase
Phase 2
Study Design
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: temsirolimus
Type: Drug
Overall Status
Recruiting
Summary
This is an open-label trial investigating the efficacy of temsirolimus in recurrent or refractory primary CNS lymphoma (PCNSL) after initial chemotherapy with a high-dose methotrexate containing regimen. 37 patients are planned to be treated with weekly infusions of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months. The trial is designed in two stages, if less than one of the first 12 patients responds to treatment, the trial is stopped. In addition to efficacy, safety and penetration of temsirolimus into the cerebrospinal fluid will be investigated.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 75 Years
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:
- Primary CNS lymphoma diagnosed histologically or by cerebrospinal fluid cytology; absence of systemic lymphoma manifestations
- Relapse or lymphoma progression after/during high-dose methotrexate containing first-line chemotherapy or alternative therapy in the case of contraindications against high-dose methotrexate
- ECOG performance score ≤ 2
- Age ≥18 years and ≤ 75 years
- Life expectancy of at least 3 months
- Absence of active infection
- Negative HIV serology
- Adequate renal function (GFR >30ml/h)
- Adequate bone marrow reserve (neutrophils > 1500/µl, platelets > 80,000/µl)
- Bilirubin <1.5x upper limit of normal (ULN), ALT and AST <3x ULN
- At least 3 weeks interval from prior cytostatic treatment
- Negative pregnancy test
- Patient accessible for treatment and follow-up
- Patient compliance
- Signed informed consent
Exclusion Criteria:
- Secondary CNS lymphoma
- Primary intraocular lymphoma
- Patient eligible for high-dose chemotherapy and autologous stem-cell transplantation
- Concurrent treatment within another clinical trial
- Concurrent other malignant disease
- Symptomatic congestive heart failure (≥NYHA II)
- Active or uncontrolled chronic infection
- Severe concomitant disease incompatible with study conduct
- History of cerebral bleeding
- Concomitant treatment with strong CYP3A4/5-inductors or -inhibitors
- Premenopausal women without highly effective contraception (defined as Pearl index <1)
- Pregnant or lactating women
- Refusal to record and pass on pseudonymized disease and treatment related data as part of the treatment protocol
- Concurrent admission to a psychiatric institution by public order
- Primary CNS lymphoma diagnosed histologically or by cerebrospinal fluid cytology; absence of systemic lymphoma manifestations
- Relapse or lymphoma progression after/during high-dose methotrexate containing first-line chemotherapy or alternative therapy in the case of contraindications against high-dose methotrexate
- ECOG performance score ≤ 2
- Age ≥18 years and ≤ 75 years
- Life expectancy of at least 3 months
- Absence of active infection
- Negative HIV serology
- Adequate renal function (GFR >30ml/h)
- Adequate bone marrow reserve (neutrophils > 1500/µl, platelets > 80,000/µl)
- Bilirubin <1.5x upper limit of normal (ULN), ALT and AST <3x ULN
- At least 3 weeks interval from prior cytostatic treatment
- Negative pregnancy test
- Patient accessible for treatment and follow-up
- Patient compliance
- Signed informed consent
Exclusion Criteria:
- Secondary CNS lymphoma
- Primary intraocular lymphoma
- Patient eligible for high-dose chemotherapy and autologous stem-cell transplantation
- Concurrent treatment within another clinical trial
- Concurrent other malignant disease
- Symptomatic congestive heart failure (≥NYHA II)
- Active or uncontrolled chronic infection
- Severe concomitant disease incompatible with study conduct
- History of cerebral bleeding
- Concomitant treatment with strong CYP3A4/5-inductors or -inhibitors
- Premenopausal women without highly effective contraception (defined as Pearl index <1)
- Pregnant or lactating women
- Refusal to record and pass on pseudonymized disease and treatment related data as part of the treatment protocol
- Concurrent admission to a psychiatric institution by public order
Locations
Charité Campus Benjamin Franklin
Berlin, Germany
Neurology, Knappschaftskrankenhaus Bochum, Bochum University
Status: Recruiting
Contact: Agnieszka Korfel, MD - +49308445 - agnieszka.korfel@charite.de
Bochum, Germany
Neurology, University Hospital Bonn
Status: Recruiting
Contact: Uwe Schlegel, MD - +49-2342993701 - simone.middelhauve@kk-bochum.de
Bonn, Germany
Hematology, Klinikum Frankfurt/Oder
Status: Recruiting
Contact: Ulrich Herrlinger, MD - +49-222828719887 - christiane.landwehr@ukb.uni-bonn.de
Frankfurt an der Oder, Germany
Hematology, University Hospital Heidelberg
Status: Not yet recruiting
Contact: Michael Kiel, MD - +4933-55484604 - melanie.binsker@klinikum-ffo.de
Heidelberg, Germany
Klinikum Grosshadern, University Hospital Munich
Status: Not yet recruiting
Contact: Gerlinde Egerer, MD - +49-6221568029 - martina.gronkowski@med.uni-heidelberg.de
Munich, Germany
Status: Recruiting
Contact: Martin Dreyling, MD - +498970955202 - carmen.carlucci@med.uni-muenchen.de
Start Date
July 2009
Completion Date
June 2014
Sponsors
Charite University, Berlin, Germany
Source
Charite University, Berlin, Germany
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page